CIK 0001750284
- Non-accelerated filer
- Smaller reporting company
Olema Oncology, Inc.
Sign in to watch- Ticker
- OLMA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 300409740
- Phone
- +1 415-651-3316
- Business address
- 365 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Olema Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-11-18 | Horn Kinney Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +89,670 | 89,670 | ||
| 2020-11-18 | Harmon Cyrus Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +179,340 | 179,340 | ||
| 2020-11-18 | CLARK IAN T Director | Grant or award · Stock Option (Right to Buy) | +21,520 | 21,520 | ||
| 2020-11-18 | BUTITTA CYNTHIA M Director | Grant or award · Stock Option (Right to Buy) | +21,520 | 21,520 | ||
| 2020-11-18 | Bohen Sean President and CEO | Grant or award · Stock Option (Right to Buy) | +538,020 | 538,020 | ||
| 2020-09-30 | Graham G. Walmsley Director | Purchase · Series C Convertible Preferred Stock | +1,183,114 | $11.06 | $13.1M | 1,183,114 |
| 2020-09-23 | Bohen Sean President and CEO | Exercise or conversion | +51,649 | $4.82 | $249K | 51,649 |
| 2020-09-23 | Bohen Sean President and CEO | Exercise or conversion · Stock Option (Right to Buy) | −51,649 | 976,316 | ||
| 2020-09-19 | Moriarty John B EVP, Ch. Legal Officer & Sec. | Grant or award · Stock Option (Right to Buy) | +252,060 | 252,060 | ||
| 2020-09-19 | Bohen Sean President and CEO | Grant or award · Stock Option (Right to Buy) | +82,931 | 82,931 | ||
| 2020-09-19 | Bohen Sean President and CEO | Grant or award · Stock Option (Right to Buy) | +1,027,965 | 1,027,965 | ||
| 2020-09-18 | RAPPAPORT ANDREW Director | Grant or award · Stock Option (Right to Buy) | +56,964 | 56,964 | ||
| 2020-09-18 | MCCORMICK FRANK Director | Grant or award · Stock Option (Right to Buy) | +56,964 | 56,964 | ||
| 2020-09-16 | BUTITTA CYNTHIA M Director | Exercise or conversion | +83,876 | $4.41 | $370K | 83,876 |
| 2020-09-16 | BUTITTA CYNTHIA M Director | Exercise or conversion · Stock Option (Right to Buy) | −83,876 | 0 | ||
| 2020-09-12 | Harmon Cyrus Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +227,859 | 227,859 | ||
| 2020-08-12 | CLARK IAN T Director | Grant or award · Stock Option (Right to Buy) | +209,690 | 209,690 | ||
| 2020-08-12 | BUTITTA CYNTHIA M Director | Grant or award · Stock Option (Right to Buy) | +83,876 | 83,876 | ||
| 2020-06-15 | Myles David C. Chief Development Officer | Grant or award | +143,472 | 591,821 | ||
| 2020-06-15 | Kushner Peter J. Chief Scientific Officer | Grant or award | +143,472 | 1,072,752 |
Page 23 of 24 · 465 trades